Long Term Consequences of Infliximab among a Sample of Spondyloarthropathic Patients Attending Baghdad Teaching Hospital

Abstract

Objective: To determine LFT, lipid profile and the increase in weight after one year of infliximab treatment among a sample of spondyloarthopathic patients attending ‘Baghdad teaching hospital’   Patients &Methods: prospective study was carried out for a period of one years  In Baghdad teaching hospital(biological unit) on 1^st of January  2016 and ending on December 2017 .A total of 120 cases Anky losing  and psoriatic arthritis on biological agent(infliximab) had two reading of liver function test  , lipid profile  and body mass index first reading at( zero week)  and second reading at (one-year) after biological agents . Results: The mean age of study sample 36±10.3,mean age of onset 29±11.5and duration 11±8.5Significance abnormality of liver function test (ALT,AST and AP) at two reading (baseline and after one year of biological agent( p=0.0001).Regarding total Cholesterol , Triglycerides ,High Density Lipoprotein & Low density  Lipoprotein (TC,TG, HDL-c and LDL-c) Significance differences(p<0.0001) were seen  after biological  therapy in study sample. Significance differences were seen regarding body mass index and weight gain after one year of follow up of patients. Conclusion: Significance rise of LFT, abnormal lipid profile and weight increment in the study sample after one year of follow up after infliximab therapy in patients with spondyloarthopathy. Recommendation: Our findings suggest the need for more prospective studies regarding the relative contribution of infliximab treatment for abnormal Liver function test, Lipid profile and weight gain 

Keywords: Patients, Infliximab, Anti-TNF agents.